| Symbol | NAMSW |
|---|---|
| Name | NEWAMSTERDAM PHARMA CO N.V. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Pharmaceutical Preparations |
| Address | GOOIMEER 2-35, NARRDEN, P7 1411 DC |
| Telephone | 35 206 2971 |
| Fax | — |
| — | |
| Website | https://www.newamsterdampharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001936258 |
| Description | NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. Additional info from NASDAQ: |
(99% Neutral) NEWAMSTERDAM PHARMA CO N.V. (NAMSW) Announces New Board Appointment
Read moreNew Form 8-K/A - NewAmsterdam Pharma Co N.V. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352233 <b>Size:</b> 213 KB <br />Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read moreNew Form 3 - NewAmsterdam Pharma Co N.V. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352209 <b>Size:</b> 17 KB
Read moreNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more(90% Positive) NEWAMSTERDAM PHARMA CO N.V. (NAMS) Announces Enrollment Update for expected Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review
Read moreNewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Read moreNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreNewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimers Association International Conference (AAIC) 2026
Read moreKooij Louise Frederika 🟡 adjusted position in 40.0K shares (2 derivative) of NewAmsterdam Pharma Co N.V. (NAMS) at $30.73 ($2.1M) Transaction Date: Jun 22, 2026 | Filing ID: 281062
Read more